– IRELAND, Athlone – Innocoll Holdings Limited, a specialty pharmaceutical company today announced the appointment of Louis Pascarella to its Board of Directors as CEO, succeeding Rich Fante, who is stepping down after and will serve as an adviser to the Board to ensure a smooth transition.
Gurnet Point Capital, a private investment firm focused on health care, wholly-owns Innocoll.
“Louis’ decades of industry experience and proven track record of creating and executing development and commercialization strategies make him the ideal leader for the next stage of Innocoll’s growth,” said Dave Moore, Partner at Gurnet Point Capital. “His long-term vision will drive Innocoll’s growth during this transformative time and position Innocoll to continue delivering meaningful impact for hospitals, physicians, and patients through Innocoll’s pipeline of pharmaceutical solutions. We thank Rich for leading the successful FDA approval of XARACOLL and look forward to continuing benefiting from his guidance as an adviser.”
About Louis Pascarella
Louis Pascarella who will retain his current role of President joined Innocoll as President in October 2020 after having served as the U.S. Head of Commercial Operations at Novo Nordisk. He has nearly 25 years of industry experience having successfully launched numerous pharmaceutical and device brands covering myriad therapeutic areas. Before his role at Novo Nordisk, he held several senior roles at Decision Resources Group and Janssen, a Johnson & Johnson company, where he worked for more than 20 years. Pascarella holds a Bachelor of Science in Psychology and Business from Albright College and an MBA from the NYU Stern School of Business.
“I am honored to assume this role and look forward to continuing working closely with the entire Innocoll team during this exciting next stage of our growth. We will continue to drive the success of our innovative drug-device XARACOLL, build our business development function and maximize value from our impressive collagen IP portfolio to help solve today’s most important challenges in acute care for patients worldwide,” said Pascarella.
He added: “Innocoll has assembled a talented, hard-working team who share my mission of innovating the hospital industry, bringing products to market that provide better outcomes for patients and enhancing efficiency for physicians and hospitals. I look forward to building upon Innocoll’s strong foundation as we enter our next chapter of growth,”
About Innocoll Holdings Limited
Innocoll Holdings Limited is a global specialty pharmaceutical company headquartered in Athlone, Ireland, with a strong presence in the Boston-Cambridge innovation hub of the United States. Innocoll Holdings Limited and its subsidiary, Innocoll Pharmaceuticals Limited, are focused on the development and commercialization of pharmaceutical technologies to meet some of today’s most important healthcare challenges.
For more information: https://www.innocoll.com/
About Gurnet Point Capital
Gurnet Point Capital is a unique healthcare fund founded by Ernesto Bertarelli and led by Christopher Viehbacher, who, together, have decades of expertise in an industry for which they share a passion, both as Chief Executives and as investors. With an initial allocation of $2 billion, GPC is investing long-term capital and supporting entrepreneurs in building a new generation of companies. Based in Cambridge, Mass., its remit is global, encompassing life sciences and medical technologies. The fund invests across all stages of product development through to commercialization and does so with an approach that is a hybrid of the venture and private equity investing strategies.
For more information: https://www.gurnetpointcapital.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.